NASDAQ:RAPTRAPT Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding RAPT Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $24.02 +1.04 (+4.53 %) (As of 08/7/2020 02:35 PM ET) Add Compare Share Today's Range$22.95Now: $24.02▼$24.5050-Day Range$21.60MA: $26.51▼$32.1852-Week Range$10.52Now: $24.02▼$51.21Volume2,979 shsAverage Volume136,322 shsMarket Capitalization$585.37 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media RAPT Therapeutics, Inc., a clinical stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company develops small molecules that are designed to modulate the critical immune responses underlying these diseases. Its lead oncology drug candidate is FLX475 for the treatment of a range of tumors; and RPT193, a CCR4 antagonist for allergic inflammatory disease. The company is also pursuing a range of targets, including general control nonderepressible and hematopoietic progenitor kinase for the treatment of cancer. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingRAPT Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $41.33, RAPT Therapeutics has a potential upside of 72.1% from its current price of $24.02.Amount of Analyst CoverageRAPT Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesRAPT Therapeutics has received 37 “outperform” votes. (Add your “outperform” vote.)Underperform VotesRAPT Therapeutics has received 26 “underperform” votes. (Add your “underperform” vote.)Community SentimentRAPT Therapeutics has received 58.73% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about RAPT Therapeutics and other stocks. Vote “Outperform” if you believe RAPT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RAPT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldRAPT Therapeutics does not currently pay a dividend.Dividend GrowthRAPT Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, RAPT Therapeutics insiders have sold 748.27% more of their company's stock than they have bought. Specifically, they have bought $129,081.00 in company stock and sold $1,094,951.00 in company stock.Percentage Held by InsidersOnly 31.00% of the stock of RAPT Therapeutics is held by insiders.Percentage Held by Institutions44.41% of the stock of RAPT Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for RAPT Therapeutics are expected to decrease in the coming year, from ($2.16) to ($2.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RAPT Therapeutics is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RAPT Therapeutics is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRAPT Therapeutics has a P/B Ratio of 7.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.48 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RAPT Previous Symbol CUSIPN/A CIKN/A Webwww.flxbio.com Phone650-489-9000Debt Debt-to-Equity RatioN/A Current Ratio10.93 Quick Ratio10.93Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.35 per share Price / Book7.17Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees64 Outstanding Shares24,370,000Market Cap$585.37 million Next Earnings Date8/13/2020 (Estimated) OptionableNot Optionable $24.02 +1.04 (+4.53 %) (As of 08/7/2020 02:35 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive RAPT News and Ratings via Email Sign-up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. RAPT Therapeutics (NASDAQ:RAPT) Frequently Asked Questions How has RAPT Therapeutics' stock been impacted by COVID-19 (Coronavirus)? RAPT Therapeutics' stock was trading at $15.73 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RAPT stock has increased by 52.7% and is now trading at $24.02. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of RAPT Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RAPT Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for RAPT Therapeutics. When is RAPT Therapeutics' next earnings date? RAPT Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for RAPT Therapeutics. How were RAPT Therapeutics' earnings last quarter? RAPT Therapeutics (NASDAQ:RAPT) posted its quarterly earnings results on Thursday, May, 14th. The company reported ($0.56) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.43) by $0.13. The business had revenue of $0.94 million for the quarter, compared to the consensus estimate of $2.50 million. View RAPT Therapeutics' earnings history. What price target have analysts set for RAPT? 6 analysts have issued 12 month price targets for RAPT Therapeutics' stock. Their forecasts range from $35.00 to $51.00. On average, they anticipate RAPT Therapeutics' share price to reach $41.33 in the next twelve months. This suggests a possible upside of 72.1% from the stock's current price. View analysts' price targets for RAPT Therapeutics. Has RAPT Therapeutics been receiving favorable news coverage? News articles about RAPT stock have been trending positive this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. RAPT Therapeutics earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about RAPT Therapeutics. Are investors shorting RAPT Therapeutics? RAPT Therapeutics saw a increase in short interest in July. As of July 31st, there was short interest totaling 923,800 shares, an increase of 11.1% from the July 15th total of 831,200 shares. Based on an average daily trading volume, of 160,300 shares, the days-to-cover ratio is presently 5.8 days. Approximately 7.0% of the shares of the stock are short sold. View RAPT Therapeutics' Current Options Chain. Who are some of RAPT Therapeutics' key competitors? Some companies that are related to RAPT Therapeutics include Turning Point Therapeutics (TPTX), Apellis Pharmaceuticals (APLS), Prestige Consumer Healthcare (PBH), Ligand Pharmaceuticals (LGND), Xencor (XNCR), Uniqure (QURE), Aurinia Pharmaceuticals (AUPH), I-Mab (IMAB), Corcept Therapeutics (CORT), INDIVIOR PLC/S (INVVY), IGM Biosciences (IGMS), Madrigal Pharmaceuticals (MDGL), Ironwood Pharmaceuticals (IRWD), Intercept Pharmaceuticals (ICPT) and Dicerna Pharmaceuticals (DRNA). View all competitors. What other stocks do shareholders of RAPT Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other RAPT Therapeutics investors own include Slack (WORK), Cisco Systems (CSCO), Myovant Sciences (MYOV), ServiceNow (NOW), NVIDIA (NVDA), Applied Genetic Technologies (AGTC), Aimmune Therapeutics (AIMT), Advanced Micro Devices (AMD), Amarin (AMRN) and Broadcom (AVGO). Who are RAPT Therapeutics' key executives? RAPT Therapeutics' management team includes the following people: Dr. Brian Russell Wong, CEO, Pres & Director (Age 47)Mr. Eric J. Hall CFA, Interim CFO & Sec. (Age 64)Steve Young Ph.D., VP of TechnologyDr. Dirk G. Brockstedt Ph.D., Chief Scientific Officer (Age 50)Ms. Erin Campany, VP of HR (Age 52) When did RAPT Therapeutics IPO? (RAPT) raised $39 million in an IPO on Thursday, October 31st 2019. The company issued 3,000,000 shares at $12.00-$14.00 per share. BMO Capital Markets, Wells Fargo Securities and UBS Investment Bank served as the underwriters for the IPO. What is RAPT Therapeutics' stock symbol? RAPT Therapeutics trades on the NASDAQ under the ticker symbol "RAPT." Who are RAPT Therapeutics' major shareholders? RAPT Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Regents of The University of California (6.45%), Asymmetry Capital Management L.P. (0.14%), Virtus ETF Advisers LLC (0.07%), UBS Group AG (0.06%), New York State Common Retirement Fund (0.04%) and SG Americas Securities LLC (0.02%). Company insiders that own RAPT Therapeutics stock include Brian Russell Wong, Dirk G Brockstedt, Group Ii Lp Column, Karen C Lam, Michael F Giordano, Wendye Robbins and William Ho. View institutional ownership trends for RAPT Therapeutics. Which institutional investors are buying RAPT Therapeutics stock? RAPT stock was purchased by a variety of institutional investors in the last quarter, including Regents of The University of California, Asymmetry Capital Management L.P., Virtus ETF Advisers LLC, UBS Group AG, New York State Common Retirement Fund, SG Americas Securities LLC, Parallel Advisors LLC, and Ameritas Investment Partners Inc.. Company insiders that have bought RAPT Therapeutics stock in the last two years include Brian Russell Wong, Group Ii Lp Column, and Wendye Robbins. View insider buying and selling activity for RAPT Therapeutics. How do I buy shares of RAPT Therapeutics? Shares of RAPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is RAPT Therapeutics' stock price today? One share of RAPT stock can currently be purchased for approximately $24.02. How big of a company is RAPT Therapeutics? RAPT Therapeutics has a market capitalization of $585.37 million. The company earns $-43,000,000.00 in net income (profit) each year or ($9.89) on an earnings per share basis. RAPT Therapeutics employs 64 workers across the globe. What is RAPT Therapeutics' official website? The official website for RAPT Therapeutics is www.flxbio.com. How can I contact RAPT Therapeutics? RAPT Therapeutics' mailing address is 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-489-9000 or via email at [email protected] This page was last updated on 8/7/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
